BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22021170)

  • 1. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly.
    Pidaparti M; Bostrom B
    Pediatr Blood Cancer; 2012 Sep; 59(3):436-9. PubMed ID: 22021170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
    Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
    Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.
    Abbott LS; Zakova M; Shaikh F; Shewaramani N; Punnett A; Dupuis LL
    Paediatr Drugs; 2015 Aug; 17(4):315-21. PubMed ID: 25862348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
    August KJ; Miller WP; Dalton A; Shinnick S
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
    Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
    Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
    Alrazzak M; Beaupin LK; Kinyoun P; Barth M
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
    Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
    Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
    Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
    MacDonald T; Kulkarni K; Bernstein M; Fernandez CV
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):341-4. PubMed ID: 26925715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Beaupin LK; Bostrom B; Barth MJ; Franklin I; Jaeger R; Kamath P; Schreiber B; Bleyer A
    Leuk Lymphoma; 2017 Apr; 58(4):766-772. PubMed ID: 27643446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
    Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
    J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
    Burke MJ; Devidas M; Maloney K; Angiolillo A; Schore R; Dunsmore K; Larsen E; Mattano LA; Salzer W; Winter SS; Carroll W; Winick NJ; Loh ML; Raetz E; Hunger SP; Bleyer A
    Leuk Lymphoma; 2018 Jul; 59(7):1624-1633. PubMed ID: 29115886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergic reactions associated with pegaspargase in adults.
    Chang A; Kim M; Seyer M; Patel S
    Leuk Lymphoma; 2016 Jul; 57(7):1665-8. PubMed ID: 26461960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
    Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
    Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
    Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
    J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
    van der Sluis IM; Brigitha LJ; Fiocco M; de Groot-Kruseman HA; Bierings M; van den Bos C; de Haas V; Hoogerbrugge PM; Tissing WJE; Veening MA; Pieters R
    J Clin Oncol; 2024 May; 42(14):1676-1686. PubMed ID: 38306592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
    Cooperation Group of Phase II Clinical Trial of PEG-Asp
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.